In vitro and in vivo characteristics of frozen/thawed neonatal pig split-skin strips: A novel biologically active dressing for areas of severe, acute or chronic skin loss

International Journal of Molecular Medicine

Volumn 19, Issue 2, 2007, Pages 245-255

  Chiarini, Anna ^a   Dal Pra, Ilaria ^a   Armato, Ubaldo ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Biological dressings; Cultured epithelial autografts; GM CSF; IL 1 ; IL 6; Neonatal pigskin; Organ culture; TGF ; TNF ; Xenografts

Indexed keywords

CYTOKINE;

ACUTE DISEASE; ANIMAL; ARTICLE; BANDAGE; BIOPSY; CHRONIC DISEASE; FREEZING; METABOLISM; NEWBORN; PATHOLOGY; SECRETION; SKIN; SKIN TRANSPLANTATION; SWINE; TISSUE CULTURE TECHNIQUE;

ACUTE DISEASE; ANIMALS; ANIMALS, NEWBORN; BIOLOGICAL DRESSINGS; BIOPSY; CHRONIC DISEASE; CYTOKINES; FREEZING; SKIN; SKIN TRANSPLANTATION; SWINE; TISSUE CULTURE TECHNIQUES;

EID: 33847780177     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.19.2.245     Document Type: Article

References (88)

1. Fisher JC: Skin - the ultimate solution for the burn wound. N Engl J Med 311: 466-467, 1984.
2. Song IC, Bertram BE, Mohn MP and Koehnlein E: Heterografts as biological dressings for large skin wounds. Surgery 59: 576-583, 1966.
3. Gallico GG III: Biologic skin substitutes. Clin Plast Surg 17: 519-526, 1990.
4. Blight A, Mountford EM, Cheshire IM, Clancy JM and Levick PL: Treatment of full skin thickness burn injury using cultured epithelial grafts. Burns 17: 495-498, 1991.
5. Hultman CS, Brinson GM, Siltharm S, deSerres S, Cairns BA, Peterson HD and Meyer AA: Allogeneic fibroblasts used to grow cultured epidermal autografts persist in vivo and sensitize the graft recipient for accelerated second-set rejection. J Trauma 41: 51-58, 1996.
6. Miller TA, Switzer WE, Foley FD and Moncrief JA: Early homografting of second-degree burns. Plast Reconstr Surg 40: 117-125, 1967.
7. Delmonico FL, Cosimi AB and Russell PS: Temporary skin transplantation for the treatment of extensive burns. Ann Clin Res 13: 373-381, 1981.
8. Clarke JA: HIV transmission and skin grafts. Lancet 1: 983, 1987.
9. Reverdin JL: Greffe epidermiques. Bull Soc Imperiale Chir 10: 483-511, 1869.
10. [No authors listed]: Making skin from sharks: early tests offer new hope for burn victims. Time 117: 53, 1981.
11. Zhang YH: Use of sheep and goatskin as biological dressing in the treatment of burns. Chung Hua Wai Ko Tsa Chih 22: 295-296, 1984.
12. Silvetti AN, Cotton C, Byrne R, Berrian JH and Fernandez Mendez A: Preliminary experimental studies of bovine embryo skin grafts. Transplant Bull 4: 25-26, 1957.
13. Switzer WE, Moncrief JA, Mills W, Order SE and Lindberg RB: The use of canine heterografts in the therapy of thermal injuries. J Trauma 6: 391-398, 1966.
14. Piccolo N, Piccolo-Lobo N, Piccolo-Daher M, et al: Use of frogskin as a temporary biological dressing. Proc Am Burn Assoc p24, 1992.
15. Sokolic IH, Farpour A, Ulin AW and Howard J: The use of heterograft skin as a biological dressing. Surg Forum 10: 847-849, 1960.
16. Kon M, Sagi A and Mahler D: Dermodress: a temporary skin substitute for coverage of exposed vital structures in the hand. Ann Plast Surg 20: 136-139, 1988.
17. Auchincloss H Jr and Sachs DH: Xenogeneic transplantation. Annu Rev Immunol 16: 433-470, 1998.
18. Bromberg BE, Song IC and Mohn MP: The use of pig skin as a temporary biological dressing. Plastic Reconstr Surg 36: 80-90, 1965.
19. Wood M and Hale HW Jr: The use of pigskin in the treatment of thermal burns. Am J Surg 124: 720-723, 1972.
20. Chang WHJ, Gomez NH and Edelstein M: Use of lyophilised pigskin for donor site cover. Br J Plast Surg 26: 147-149, 1973.
21. Silverstein P: Evaluation and preparation of formalin-fixed cutaneous grafts as a temporary wound cover for burned soldiers. US Army Institute of Surgical Research Annual Progress Report, FY, BAMC, Fort Sam, Houston, TX, Section 34, 1972.
22. Elliott RA Jr and Hohen JG: Use of commercial porcine skin for wound dressings. Plast Reconstr Surg 52: 401-405, 1973.
23. Kaisary AV: A temporary biological dressing in the treatment of varicose ulcers and skin defects. Postgrad Med J 53: 672-673, 1977.
24. Morris DM, Hall GM and Elias EG: Porcine heterograft dressings for split-thickness graft donor sites. Surg Gynecol Obstet 149: 893-894, 1979.
25. Basile AR: A comparative study of glycerinized and lyophilized porcine skin in dressings for third-degree burns. Plast Reconstr Surg 69: 969-974, 1982.
26. Zhu DA and Cao QD: Chlorhexidine (hibitane)-alcohol refrigerated porcine skin - a simple and long-term stored xenograft. Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih 2: 203-206, 1986.
27. Mu XX: Treatment of full-thickness burn by planned replacement using glutaraldehyde porcine skin with an autograft. Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih 5: 193-196, 1989.
28. Tang ZY: Irradiated porcine skin in the treatment of second-degree burn. Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih 6: 187-188, 1990.
29. Li G, Cao Y and Wu X: Experimental study of radiated pigskin incorporated with norfloxacin and silver. Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih 10: 206-208, 1994.
30. Aronoff M, Fleishman P and Simon DL: Experience in the application of porcine xenografts to split-graft donor sites. J Trauma 16: 280-283, 1976.
31. Salisbury RE, Wilmore DW, Silverstein P and Pruitt BA Jr: Biological dressings for skin graft donor sites. Arch Surg 106: 705-706, 1973.
32. Lawrence JC: Dressings for burns. In: Principles and Practice of Burn Management. Settle J (ed). Churchill Livingstone, New York, pp259-269, 1996.
33. Rappaport I, Pepino AT and Dietrick W: Early use of xenografts as a biologic dressing in burn trauma. Am J Surg 120: 144-148, 1970.
34. Burd A: Glycerolised allogenic skin: transplant or dressing? A medico-legal question. Burns 28 (suppl 1): 34-39, 2002.
35. Habal MB: (Editorial) On the cutaneous porcine heterograft. Plast Reconstr Surg 57: 367-368, 1976.
36. German JD, Wooley TE, Achauer B, Fornas DW and Bartlett RH: Porcine xenograft burn dressings. A critical reappraisal. Arch Surg 104: 806-808, 1972.
37. Breach NM, Davies DM and Yiacoumettis A: Study of effects of porcine skin and bovine dermis on the healing of split-skin graft donor sites in humans. Plast Reconstr Surg 63: 546-549, 1979.
38. Levine NS, Lindberg RA, Salisbury RE, Mason AD Jr and Pruitt BA Jr: Comparison of coarse mesh gauze with biologic dressings on granulating wounds. Am J Surg 131: 727-729, 1976.
39. Chiu T and Burd A: 'Xenograft' dressing in the treatment of burns. Clin Dermatol 23: 419-423, 2005.
40. Department of Health and Human Services, Public Health Service, Draft Public Health Service (PHS): Guideline on Infectious Disease Issues in Xenotransplantation. Federal Register 61: 49920-49932, 1996.
41. World Health Organization (WHO): Xenotransplantation: Guidance on Infectious Disease Prevention and Management. WHO, Geneva, Switzerland, 1998.
42. Qari SH, Magre S, Garcia-Lerma JG, Hussain AI, Takeuchi Y, Patience C, Weiss RA and Heneine W: Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors. J Virol 75: 1048-1053, 2001.
43. Trinder P: Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 22: 158-161, 1969.
44. Barham D and Trinder P: An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst 97: 142-145, 1972.
45. Jackson P and Blythe D: Immunolabelling techniques for light microscopy. In: Immunocytochemistry: A Practical Approach. Beesley JE (ed). IRL Press at Oxford University Press, Oxford, pp15-41, 1995.
46. Bancroft JD and Cook HC: Manual of Histological Techniques and their Diagnostic Application. Churchill Livingstone, Edinburgh, p27 and pp243-244, 1994.
47. II is an apoptotic lamin kinase in polyomavirus-transformed, etoposide-treated pyF111 rat fibroblasts. J Biol Chem 277: 18827-18839, 2002. Epub March 18, 2002.
48. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
49. Zielke HR, Ozand PT, Tildon JT, Sevdalian DA and Cornblath M: Reciprocal regulation of glucose and glutamine utilization by cultured human diploid fibroblasts. J Cell Physiol 95: 41-48, 1978.
50. Holman DM and Kalaaji AN: Cytokines in dermatology. J Drugs Dermatol 5: 520-524, 2006.
51. Green D, Law E and Still JM: An approach to the management of toxic epidermal necrolysis in a burn centre. Burns 19: 411-414, 1993.
52. Dinarello CA: The biological properties of interleukin-1. Eur Cytokine Netw 5: 517-531, 1994.
53. Sims J, Towne J and Blumberg H: IL-1 family members in inflammatory skin disease. Ernst Schering Res Found Workshop 56: 187-191, 2006.
54. Paquet P and Pierard GE: Interleukin-6 and the skin. Int Arch Allergy Immunol 109: 308-317, 1996.
55. Hernandez-Quintero M, Kuri-Harcuch W, Gonzalez Robles A and Castro-Munozledo F: Interleukin-6 promotes human epidermal keratinocyte proliferation and keratin cytoskeleton reorganization in culture. Cell Tissue Res 325: 77-90, 2006. Epub ahead of print March 21, 2006.
56. Brauchle M, Angermeyer K, Hubner G and Werner S: Large induction of keratinocyte growth factor expression by serum growth factors and pro-inflammatory cytokines in cultured fibroblasts. Oncogene 9: 3199-3204, 1994.
57. Fehgali CA, Bost KL, Boulware DW and Levy LS: Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblasts. Clin Immunol Immunopathol 63: 182-187, 1992.
58. Mann A, Breuhahn K, Schirmacher P and Blessing M: Keratinocyte-derived granulocyte-macrophage colony stimulating factor accelerates wound healing: Stimulation of keratinocyte proliferation, granulation tissue formation, and vascularization. J Invest Dermatol 117: 1382-1390, 2001.
59. Trent JT and Kerdel FA: Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs 17: 97-107, 2005.
60. Faler BJ, Macsata RA, Plummer D, Mishra L and Sidawy AN: Transforming growth factor-beta and wound healing. Perspect Vasc Surg Endovasc Ther Mar 18: 55-61, 2006.
61. Leask A and Abraham DJ: TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827, 2004.
62. Kirsner RS, Falanga V and Eaglstein WH: The biology of skin grafts. Skin grafts as pharmacologic agents. Arch Dermatol 129: 481-483, 1993.
63. Heneine W, Tibell A, Switzer W, Sandstrom P, Rosales GV, Mathews A, Korsgren O, Chapman LE, Folks TM and Groth CG: No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet 352: 695-699, 1998.
64. Kagan RJ: FDA regulation of human tissue: implications for skin banks and burn centers. J Burn Care Rehabil 21: 353-357, 2000.
65. Parravicini C, Olsen SJ, Capra M, Poli F, Sirchia G, Gao SJ, Berti E, Nocera A, Rossi E, Bestetti G, Pizzuto M, Galli M, Moroni M, Moore PS and Corbellino M: Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood 90: 2826-2829, 1997.
66. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RYand Busch MP; National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group: Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 351: 760-768, 2004.
67. Mohan J, Brown KL, Farquhar CF, Bruce ME and Mabbott NA: Scrapie transmission following exposure through the skin is dependent on follicular dendritic cells in lymphoid tissues. J Dermatol Sci 35: 101-111, 2004.
68. Lomas RJ, Jennings LM, Fisher J and Kearney JN: Effects of a peracetic acid disinfection protocol on the biocompatibility and biomechanical properties of human patellar tendon allografts. Cell Tissue Bank 5: 149-160, 2004.
69. Eastlund T: Infectious disease transmission through cell, tissue, and organ transplantation: Reducing the risk through donor selection. Cell Transplant 4: 455-477, 1995.
70. Goddard MJ, Foweraker JE and Wallwork J: Xenotransplantation-2000. J Clin Pathol 53: 44-48, 2000.
71. Weiss RA: Xenografts and retroviruses. Science 285: 1221-1222, 1999.
72. Patience C, Patton GS, Takeuchi Y, Weiss RA, McClure MO, Rydberg L and Breimer ME: No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet 352: 699-701, 1998.
73. Pitkin Z and Mullon C: Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. Artif Organs 23: 829-833, 1999.
74. Elliott RB, Escobar L, Garkavenko O, Croxson MC, Schroeder BA, McGregor M, Ferguson G, Beckman N and Ferguson S: No evidence of infection with porcine endogenous retrovirus in recipients of encapsulated porcine islet xenografts. Cell Transplant 9: 895-901, 2000.
75. Dinsmore JH, Manhart C, Raineri R, Jacoby DB and Moore A: No evidence for infection of human cells with porcine endogenous retrovirus (PERV) after exposure to porcine fetal neuronal cells. Transplantation 70: 1382-1389, 2000.
76. Levy MF, Crippin J, Sutton S, Netto G, McCormack J, Curiel T, Goldstein RM, Newman JT, Gonwa TA, Banchereau J, Diamond LE, Byrne G, Logan J and Klintmalm GB: Liver allotransplantation after extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers: clinical results and lack of pig-to-human transmission of the porcine endogenous retrovirus. Transplantation 69: 272-280, 2000.
77. Xu H, Sharma A, Okabe J, Cui C, Huang L, Wei YY, Wan H, Lei Y, Logan JS, Levy MF and Byrne GW: Serologic analysis of anti-porcine endogenous retroviruses immune responses in humans after ex vivo transgenic pig liver perfusion. ASAIO J 49: 407-416, 2003.
78. Magre S, Takeuchi Y and Bartosch B: Xenotransplantation and pig endogenous retroviruses. Rev Med Virol 13: 311-329, 2003.
79. Irgang M, Sauer IM, Karlas A, Zeilinger K, Gerlach JC, Kurth R, Neuhaus P and Denner J: Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells. J Clin Virol 28: 141-154, 2003.
80. Denner J: Porcine endogenous retroviruses (PERVs) and xenotransplantation: screening for transmission in several clinical trials and in experimental models using non-human primates. Ann Transplant 8: 39-48, 2003.
81. McKane BW, Ramachandran S, Xu XC, Olack BJ, Chapman WC and Mohanakumar T: Natural antibodies prevent in vivo transmission of porcine islet-derived endogenous retrovirus to human cells. Cell Transplant 13: 137-143, 2004.
82. Fishman JA and Patience C: Xenotransplantation: Infectious risk revisited. Am J Transplant 4: 1383-1390, 2004.
83. Boneva RS and Folks TM: Xenotransplantation and risks of zoonotic infections. Ann Med 36: 504-517, 2004.
84. Di Nicuolo G, van de Kerkhove MP, Hoekstra R, Beld MG, Amoroso P, Battisti S, Starace M, di Florio E, Scuderi V, Scala S, Bracco A, Mancini A, Chamuleau RA and Calise F: No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver. Xenotransplantation 12: 286-292, 2005.
85. Winkler ME, Winkler M, Burian R, Hecker J, Loss M, Przemeck M, Lorenz R, Patience C, Karlas A, Sommer S, Denner J and Martin U: Analysis of pig-to-human porcine endogenous retrovirus transmission in a triple-species kidney xenotransplantation model. Transpl Int 17: 848-858, 2005. Epub April 29, 2005.
86. Karlas A, Kurth R and Denner J: Inhibition of porcine endogenous retroviruses by RNA interference: increasing the safety of xenotransplantation. Virology 325: 18-23, 2004.
87. Miyagawa S, Nakatsu S, Nakagawa T, Kondo A, Matsunami K, Hazama K, Yamada J, Tomonaga K, Miyazawa T and Shirakura R: Prevention of PERV infections in pig to human xenotransplantation by the RNA interference silences gene. J Biochem 137: 503-508, 2005.
88. Miyagawa S, Nakatsu S, Hazama K, Nakagawa T, Kondo A, Matsunami K, Yamamoto A, Yamada J, Miyazawa T and Shirakura R: A novel strategy for preventing PERV transmission to human cells by remodeling the viral envelope glycoprotein. Xenotransplantation 13: 258-263, 2006.